Introduction
The RET gene encodes 2 isoforms of a transmembrane receptor endowed with tyrosine kinase activity (Iwamoto et al., 1993; Takahashi et al., 1989) . The Ret protein comprises a 635 amino acids extracellular domain, that consists of a N-terminal cadherin-like region and a Cys rich sequence, a single transmembrane spanning region and an intracellular TK domain that contains a 26 amino acids kinase insert and a Cterminal region (Iwamoto et al., 1993) . The two isoforms dier in the C-terminal region displaying 9 or 51 unrelated amino acids respectively, from residue 1063 to the C-terminal end.
Additional splicing forms of RET immature RNA have been reported (Myers et al., 1995) , but, so far, no evidence of the relative translation products has been provided. RET gene is highly expressed in the developing central and peripheral nervous system in the excretory system of the mouse embryo (Tsuzuki et al., 1995) and is involved in the control of neural crest development and kidney organogenesis, as suggested by knock out experiments (Schuchardt et al., 1994) .
Ret ligands have been recently identi®ed as Glial Derived Neurotrophic Factor (GDNF) (Durbec et al., 1996; Trupp et al., 1996) , known as a potent survival factor of several neuronal populations (Lin et al., 1993) and Neurturin, a neurotrophic factor 42% identical to GDNF . Ret activation seems to be mediated also by at least two dierent GPI-linked co-receptor proteins, named GDNFR-a1 (Jing et al., 1996; Treanor et al., 1996) , -a2 Suvanto et al., 1997) and -a3 (Jing et al., 1997) .
Physical and genetic mapping data and biological assays have involved RET gene in ®ve dierent diseases. In the inherited cancer syndromes MEN (Multiple Endocrine Neoplasia) 2A and FMTC (Familial Medullar Thyroid Carcinomas) a Cys substitution in the Cys rich region, causing a constitutive dimerisation and activation of Ret TK, have been identi®ed whereas MEN2B is associated with a single missense mutation in the TK domain responsible for dierent Tyr auto-phosphorylation sites and substrate speci®ties. A non neoplastic inherited disease involving RET, congenital megacolon or Hirschsprung's (HSCR) disease, comprises a broad spectrum of RET gene alterations, all determining loss of its activity function . Finally, about 35% of Papillary Thyroid Carcinomas, displays RET gene somatically rearranged with dierent donor genes, designated RET/PTCs, inducing a constitutive dimerisation and consequent activation of the Ret tyrosine kinase Lanzi et al., 1992) . These ®ndings demonstrate the signi®cant involvement of Ret in dierent human diseases and strongly indicate the need to de®ne its associate signal transduction pathway(s).
Since Ret ligands have been only recently identi®ed, the intracellular signaling triggered by Ret kinase has been so far investigated using either an EGFR ± RET chimera or RET/PTC oncogenes. Following these approaches, it has been determined that Ret interacts and activates the adaptor protein Shc and the Phospholipase Cg (Borrello et al., 1996; Arighi et al., 1997) . The binding sites of these proteins, as well as the binding sites for Grb10 (Pandey et al., 1995) and LIM2 (Durick et al., 1995) have been identi®ed on Ret sequence. The activation of the ras-ERK pathway by Ret protein is less clear. Activation of p21-ras by receptor tyrosine kinases is mediated by the guanine nucleotide exchanger SOS, which forms a complex with Grb2. The latter is activated by binding either to the tyrosine phosphorylated receptor or to the tyrosine phosphorylated Shc (Pronk and Bos, 1994) . p21-ras can in turn activate ERK2 via Raf . The ability of Ret to activate Shc and to trigger its subsequent association with Grb2 has been demonstrated using either Ret/ptc or EGFR-Ret chimera van Weering et al., 1995) . In addition, ras and ERK2 activation were demonstrated using a neuroectodermal-derived cell line expressing EGFR-Ret chimera (van Weering et al., 1995) , whereas only ras activation was evident in a ®broblast background . Moreover, on the basis of sequence data (Songyang et al., 1993) , a putative Grb2 docking site has been identi®ed only on Ret long isoform at tyrosine 1096 of proto Ret, corresponding to tyrosine 620 on Ret/ptc2.
To contribute to a better understanding of Ret signaling, in general, and in particular, to further de®ne Grb2-Ret interaction and to identify the docking sites of Grb2 on Ret sequence, we have used both isoforms of the dierent activated versions of Ret and classical experiments of phosphopeptide competition of in vitro binding and site-directed mutagenesis on the relevant receptor tyrosine residues.
Results
The two Ret/ptc2 isoforms display a dierent anity for Grb2 ± SH2 domain
To study the role of Grb2 in the transforming pathway triggered by Ret oncoproteins, we have investigated the interaction of Grb2 with either Ret isoforms, in vitro and in intact cells. To this aim we have used Ret/ptc2, a cytoplasmic oncoprotein encoded by RET/PTC2 oncogene isolated from Papillary Thyroid Carcinomas, and RetC634R, a membrane bound activated form of the receptor, associated to MEN2A syndrome. We had previously demonstrated that the Grb2 SH2 domain binds both the isoforms of Ret/ptc2 Figure 1 In vitro binding of Ret/ptc2 (b) or Ret-MEN2A (c) isoforms to Grb2-SH2 domain. (a): Schematic representation of iso9 and iso51 Ret/ptc2 and proto Ret isoforms. The introduced mutation converting tyrosine 620 of Ret/ptc2 to phenylalanine is indicated. b,c: The experiments were performed using Sepharose-bound Gst or Gst fusion protein bearing the SH2-Grb2 domain, (as indicated) and protein extracts from NIH3T3 cell lines expressing separately the two isoforms of Ret/ptc2 (wt-iso9 or wt-iso51) or proto Ret carrying the C634R mutation (Ret2A iso9 or Ret2A iso51). In (b) the indicated amounts of Ret/ptc2 wt-iso9 or wtiso51 expressing protein extracts were used; 0.5 mg of the same extracts were immunoprecipitated with anti-Ret antiserum as control. In (c) 1 mg of proto Ret-MEN2A short (iso9) or long (iso51) isoforms expressing protein extract were used. IP/BP: immunoprecipitation or binding protein. Arrowheads indicate p76 and p81 Ret/ptc2 isoforms and gp150 and gp170 Ret 2A glycoproteins. In panel (b) the immunoreactive bands were visualized using 125 I-labeled protein A and the ®lters were exposed with PhosphorImager apparatus Figure 1a .
By using a constant amount (40 mg) of Gst protein fused to Grb2 ± SH2 domain and increasing amounts of Ret/ptc2 containing extracts derived from two NIH3T3 cell lines expressing either Ret/ptc2 iso9 or iso51 oncogenic forms, we have found that the long isoform binds Grb2 ± SH2 domain about 25 ± 50 times more than the short one, as estimated by PhosphorImager analysis (Figure 1b ) (see Materials and methods). A similar result was obtained (Figure 1c ) by using the activated, membrane associated Ret C634R receptor protein (Ret carrying the MEN2A mutation). This result suggests, therefore, that although the two Ret versions display a dierent cellular localization, they show the same interaction with Grb2-SH2 domain. The weak, but reproducible binding to Grb2 of the receptorial version of Ret iso9 protein indicates that the binding between Grb2 and Ret/ptc2 could not be due to its 5' end-RIa derived sequence, as it could be hypothesized following a recent report about Grb2-RIa protein interaction (Tortora et al., 1997) , but instead it should be attributed to an interaction with the C-terminus of Ret protein itself.
Identi®cation of putative docking site(s) for Grb2 ± SH2 domain
To determine the putative Grb2 binding site(s) on Ret protein, a series of synthetic phosphopeptides, corresponding to the residues in the C-terminal region of both Ret isoforms were used in competition assays (Figure 2 ). The phosphopeptides were already used in Borrello et al. (1996) , and Arighi et al. (1997) and are described in Materials and methods. The experiments were performed using the indicated amount of phosphopeptides, Gst-SH2 ± Grb2 fused protein and NIH3T3 cell lysates containing both the Ret/ptc2 isoforms.
As shown in Figure 2a , only the peptide containing Tyr 620 of Ret/ptc2 (Tyr 1096 on proto-Ret), inhibits the binding. Moreover, a dose dependent inhibition of pY620 peptide was observed and at the concentration of 50 mM the Grb2 ± SH2 domain-Ret oncoprotein binding was completely abolished, as reported in Figure 2b . Tyr 1096 is one of the two iso51 speci®c tyrosines, the second one being the Tyr 1090, both sitting within the consensus for Grb2 binding. However, tyrosine 1096 but not tyrosine 1090 was demonstrated to be phosphorylated in activated Ret kinase and thus it has been suggested to represent the docking site of Grb2 ± SH2 domain (Liu et al., 1996; Lorenzo et al., 1997) . Accordingly, the corresponding pY614 peptide was not inhibitory in our assay ( Figure  2b ). 
Shc and Syp molecules as candidate adaptor proteins for Grb2 binding to Ret
As inferred from peptide inhibition experiments, a direct binding to the Grb2 ± SH2 domain is postulated only for isoform 51 but not for isoform 9 of Ret. Accordingly, in Figure 4b it is shown that only the binding of isoform 51 to the Grb2 ± SH2 domain is conformation independent. In fact, the weak but reproducible interaction of the short isoform with the Grb2-SH2 domain is abolished by SDS boiling treatment. Therefore, we have investigated whether SHP2/PTP1D/Syp (Feng et al., 1993) , a phosphotyrosine phosphatase known to mediate the binding of Grb2 to PDGF receptor (Li et al., 1994) , could be an adaptor protein also for Grb2 binding to Ret. As shown in Figure 3a right panel, no binding to Syp was detected for either isoform. In the left panel is shown, as positive control, the binding between PDGF receptor and Syp. In the experiment shown in this ®gure the Syp-SH2N terminal domain was used, the same result was however obtained also by using the Syp-SH2C terminal domain (data not shown).
On the contrary, Shc adaptor protein, known to mediate Grb2 binding even in the presence of a direct docking site, as in the case of EGFR , has been reported to bind either Ret isoforms (Arighi et al., 1997; Lorenzo et al., 1995) . Here we con®rm this conclusion by showing in Figure 3b the Shc interaction with Ret in coimmunoprecipitation experiments: both isoforms are able to bind and phosphorylate Shc that could thus mediate the binding of Ret/ptc2 to Grb2.
Construction of the RET/PTC2Y620F mutant and its biological eect on NIH3T3 cells
Since Tyr 620 inhibits the in vitro binding of Ret protein to the Grb2-SH2 domain, this residue was chosen as target for site-speci®c mutagenesis to eliminate the putative Grb2 docking site on Ret/ptc2 oncoprotein. The location of Tyr620 in Ret/ptc2 as well as that of the corresponding Tyr on protoRet protein (Tyr1096) was anticipated on Figure 1a .
The Tyr 620-Phe mutation was introduced by site directed mutagenesis in the RET/PTC2 cDNA encoding the long isoform (Arighi et al., 1997) . A full-length RET/PTC2-iso51Y620F cDNA clone was entirely sequenced and was demonstrated to dier from the RET/PTC2ISO51 WT only for the introduced missense mutation (data not shown).
The RET/PTC2-iso51Y620F was then cloned in pRC-CMV eukaryotic vector, carrying the neomycin resistance gene. The mutant RET oncogene construct and its corresponding WT version, were transiently expressed in COS7 cells in order to verify the synthesis of the correctly sized (81 kD) product and to compare the biochemical characteristics of the two proteins.
As shown in Figure 4a (left panel) the mutated protein displays the same size and the same steady state phosphorylation level of Ret/ptc2 wt protein.
The additional slower migrating protein species is due to the vector characteristics as previously discussed and being present in both the wt and the mutant forms, does not in¯uence the observed results. Moreover, when analysed by in vitro immunokinase assay, wt and mutated protein showed comparable autophosphorylation and substrate-phosphorylation activities on MBP (Figure 4a right panel) .
In order to investigate the biological eect of the mutant protein, NIH3T3 cells were stably transfected with the above described pRC-CMV constructs. The capability of RET/PTC2-WTISO51-and RET/PTC2-iso51Y620F to induce cell transformation foci were compared. RET/PTC2-ISO51-Y620F showed a strong reduction of transforming activity (about 70%), evaluated as number of transformation foci, in comparison with the activity of RET/PTC2-ISO51WT (Table 1 ). The two isoforms of the RET/ PTC2 oncogenes display a similar transforming activity (data not shown). (a) Expression, tyrosine phosphorylation and in vitro immunocomplex kinase assay of Ret/ptciso512wt-and Ret/ ptc2Yiso51620F-, transiently transfected in COS7 cells. The kinase activity was assayed also on Myelinic Basic Protein (MPB) (b) In vitro binding of Ret/ptc2Y620F-iso51 mutant to Grb2-SH2 domain. Protein extracts from NIH3T3 cell lines expressing either isoform of Ret/ptc2 (wt-iso9 and wt-iso51) or Ret/ptciso51Y620F-mutant were used in a binding experiment using Sepharose bound Gst or Gst-SH2-Grb2 fusion protein. The samples were untreated (lane 7) or boiled in presence of 1% SDS (lanes 1008C+SDS) before the binding. The same extracts were immunoprecipitated with anti-Ret antiserum, as control Tyr620 is therefore essential for the full transforming activity of Ret/ptc2-iso51-wt oncoprotein, thus indicating that this tyrosine is a docking site for SH2-bearing molecules necessary for iso51 signaling.
Stable cell lines expressing both the wt isoforms and the mutant Ret/ptc2 were obtained to analyse the ability of Ret/ptc2-iso51-Y620F mutant to bind Grb2 protein. Cell extracts containing Ret/ptc2wt short or long isoform or Ret/ptc2-iso51-Y620F, were boiled in presence of 1% SDS or untreated and incubated with Gst-SH2-Grb2 fused protein. As shown in Figure 4b , Ret/ptc2iso51wt (wt-iso51) binds directly the Grb2-SH2 domain. Ret/ptc2-iso9wt (wt-iso9) as well as Ret/ ptc2-iso51Y620F (Y620F) shows only a weak interaction that disappears after SDS treatment. The Y620F mutation, therefore, clearly abolishes the ability of Ret/ptc2 long isoform to bind the Grb2-SH2 domain in vitro.
Analysis of Ret-Grb2 interactions in intact cells and in cell extracts by using the whole Gst-Grb2 protein
To analyse the ability of the dierent forms of Ret protein to interact with Grb2 in intact cells, we have used cells expressing short or long isoform of Ret/ptc2 wt oncoproteins, Ret/ptc2-Y620F mutant and the two isoforms of the membrane associated Ret receptor carrying the MEN2A mutation. As shown in Figure  5a , the mutant Ret/ptc2-iso51-Y620F, although not completely, loses the ability to coimmunoprecipitate with Grb2, thus con®rming in vivo the results obtained in vitro. However, at variance with the in vitro results, by comparing the coimmunoprecipitation of Grb2 with long or short isoforms either derived from Ret/ ptc2 (Figure 5a ) or from Ret2A (data not shown) we have found a comparable binding of the two isoforms. The coimmunoprecipitation was detected exclusively by using a very sensitive system (Perkin Elmer, see Materials and methods) but in three repeated experiments, comparable amount of the two isoforms were detected whereas only a faint band related the Y620F mutant protein was observed. The reciprocal experiment is shown in panel b of the same ®gure where immunoprecipitates anti-Grb2 from cell lines expressing short or long isoform of Ret/ptc2 oncoproteins were blotted with antiphosphotyrosine antiserum to detect phosphorylated Ret proteins bound to Grb2. Low and similar amounts of the two isoforms coimmunoprecipitating with Grb2 were detected together with a number of unidenti®ed phosphotyrosine containing proteins (Figure 5b) .
Since, by using the Grb2 ± SH2 domain, the dierence in the binding between the two isoforms was at least of one order of magnitude (Figure 1b and  c) , whereas the two Ret isoforms display a similar coimmunoprecipitation with Grb2 in living cells (Figure 5a and b) , we used the whole Grb2 fused to Gst to analyse its binding to Ret/ptc2 isoforms. As shown in Figure 5c , by using the described approach, we observed again a dierence by comparing the two isoforms. In any case, in repeated experiments, the two isoforms showed a stronger binding to the whole Grb2 molecule, than to its SH2 domain (data not shown).
The experiments shown in Figure 6 and whose semi-quantitative analysis is reported in Table 2 , were performed by using separated Grb2 domains and by developing blots with iodinated protein A with the aim to investigate the following points: (1) To de®ne whether additional domains of Grb2 other than SH2 aect Grb2 binding to Ret/ptc2; (2) To compare and quantify the Grb2 binding of the two Ret isoforms by using dierent domains of Grb2 to better de®ne their interactions; (3) To de®ne the role of the tyrosine Y586 of Ret/ptcz, (Y1062 of protoRet) whose Cterminal sequence is isoform-9 -speci®c in Grb2 binding, by using RET/PTC2-iso9Y586F mutant; (4) To quantify the residual binding to Grb2 of the long isoform devoided of Tyr620, the canonical direct docking site for the Grb2-SH2 domain.
The relative results were as follows: (1) We have found that the Grb2-SH2 domain accounts for only 15% of the binding of the whole Grb2 for both isoforms, as estimated by PhosphorImager analysis, whereas for another constitutively activated oncoprotein, used as control, Tpr-met, Grb2-SH2 domain accounts for 100% of binding to Grb2 in the same experiments. However, when the Grb2-SH3 C-terminal or N-terminal domains were used, neither Tpr-met nor Ret isoforms were detected as bound proteins. As control, the same blots were hybridized with anti-SOS antiserum and SOS protein was detected in all SH3C, SH3N and full Grb2 lanes (data not shown); (2) As already shown in Figure 1b , Ret/ptc2 iso51 binds the SH2 domain of Grb2 better than the corresponding iso9 (about one order of magnitude in this test). A similar result was obtained by using a fusion protein with full Grb2. In fact, even if full Grb2, as already observed, binds Ret/ptc2 proteins more eciently than the SH2 domain alone, the amount of long isoform bound is about six times the amount of the short one; (3) The Ret/ptc2-iso9Y586F mutant loses 67 and 86% of binding to Grb2-SH2 domain and to full Grb2, respectively, when compared to the Ret/ptc2-iso9wt, thus suggesting a role for this docking site for Grb2 binding to the iso9 isoform. Subsequently, we have produced Ret/ptc2-iso51Y586F, the corresponding mutant in the long isoform and we have shown that, this mutant that maintains the tyrosine 620, binds Grb2 as well as the wt version (data not shown); (4) Ret/ptc2-iso51Y620F loses almost completely, 92% and 100%, of its binding capacity to full Grb2 or to Grb2-SH2, respectively.
Discussion
In this paper we have analysed the interaction between Grb2 and Ret by using either Ret isoforms, which dier in their C-terminal tails by displaying nine and 51 isoform-speci®c amino acids and named iso9 (short) or iso51 (long) isoforms, respectively (Tahira et al., 1990) . The experiments were performed with constitutively activated oncogenic Ret versions, encoded by RET/PTC2 (Bongarzone et al., 1993) , a thyroid carcinoma-speci®c oncogene generated by a somatic rearrangement of RET and by RET-C634R , a RET point mutant associated to the inherited cancer syndrome MEN2A. The two oncogenic proteins represent cytosolic and membranebound forms of Ret kinase, respectively.
Based on the consensus for the SH2 of Grb2, pYXN (songyang et al., 1993) a direct docking site for Grb2 could be predicted only on the long isoform of Ret. Inhibition experiments of in vitro binding between Ret/ptc2 and the SH2 of Grb2, by using synthetic phosphopeptides modeled on Ret-iso9 and Ret-iso51 sequences, con®rmed this prediction. In fact, only pY620 (corresponding to tyrosine residue 620 of Ret/ptc2 and 1096 of protoRet) was able to inhibit the binding. The phosphopeptide pY614 was not eective, although its sequence ®ts with the consensus YXN. It could be suggested that the surrounding amino acids could impair this tyrosine to function as docking site. In agreement with this possibility, Liu et al. (1996) have demonstrated that the corresponding Tyr (Y1090) is not phosphorylated in Ret activated by MEN2A mutation. To prove that Tyr620 was indeed the Grb2 docking site, the mutant Ret/ptc2iso51-Y620F was produced and demonstrated to lose completely the ability to directly bind the SH2 domain of Grb2, whereas it maintains a very low but detectable ability to bind indirectly in vitro Gstfused full Grb2 protein and to coimmunoprecipitate with Grb2 in living cells. Similar results were obtained by Liu et al. (1996) by mutagenising Tyr 1096 on RETC634R gene. These authors, however, did not address the question of whether this binding was direct, mediated or, as we have shown here, whether both types of interaction are detectable.
Since the mutation abrogating the direct binding with Grb2 was inserted in Ret/ptc2, an oncogenic version of Ret, RET/PTC2-ISO51Y620F mutant, was tested in transfection assay on NIH3T3 cells. The transforming ability of this mutant, evaluated as number of morphological foci induced on NIH3T3 cells, was reduced by about 70%. This result suggests that Tyr620 is essential for the full transforming activity of Ret/ptc2-iso51 oncoprotein, thus indicating that this tyrosine is a docking site for SH2-bearing molecule(s) essential for iso51 oncogenic signaling. Moreover, since we have repeatedly observed that WT short and long isoforms of Ret/ptc2 induce the same number of transformation foci on NIH3T3 cells (data not shown), this result suggests that the function of Tyr620 in the short isoform is provided by another sequence that remains to be identi®ed but that is predicted to be iso9-speci®c.
The modalities of binding between Grb2 and Retiso9 are more elusive. The in vitro experiments using Ret/ptc2 or RetC634R indicated that the short isoform binds the Grb2 ± SH2 domain less eciently (one order of magnitude) than the long one. However, in disagreement with the in vitro results, coimmunoprecipitation experiments in living cells between Grb2 and the Ret isoforms in both direction, showed comparable levels of Grb2 binding to the two isoforms.
In the attempt to explain the dierent results obtained in vitro using the Grb2 ± SH2 domain and by coimmunoprecipitation in living cells, we have compared the binding of short and long Ret isoforms to Gst proteins fused with full Grb2 or with all its domains separately expressed. We have indeed demonstrated that the Grb2 ± SH2 domain accounts for only 11% of Ret/ptc2-iso9 binding with full Grb2, whereas, as expected, it accounts for 100% of Tpr/met binding used as positive control. However, the binding of Ret/ptc2-iso51 to Grb2 was similar to that of the iso9, with the Grb2 ± SH2 domain accounting for only about 16% of its binding to full Grb2. In addition, neither the C-terminal nor the N-terminal Grb2 ± SH3 domain bind Ret in vitro. By all the above results, we have therefore deduced that Ret/ptc2 binding with Grb2 ± SH2 is in some way`stabilized' by one or both SH3 domains or by Grb2 secondary structure. An involvement of SH3 domains for binding of Grb2 to receptor tyrosine kinase was not previously reported while a similar result was recently obtained by den Hertog and Hunter (1996) for Grb2 binding to receptor protein-tyrosine phosphatase a. Also in this case, isolated SH3 domains did not bind the phosphatase but, instead, the presence of C-terminal SH3 domain was demonstrated to be necessary. Moreover, since at variance with the in vivo results, even using full Grb2, the short isoform binds Grb2 less eciently in vitro than the long one, we must attribute this discrepancy to dierences due to the particular features of the Gst system. We could hypothesize, for example, that Grb2 fused protein immobilized on Glutathione-Sepharose have a conformation dierent from that of the Grb2 protein in the cell, still allowing ecient binding for Ret/ptc2-iso51, largely conformation-independent, but not for Ret/ptc2-iso9. Alternatively, since (as it will be discussed later) Ret/ptc2-iso9 binding to Grb2 is probably not direct, it could be that the binding between Grb2 and this`adaptor molecule(s)' is strong, not allowing it (them) to bridge eciently Ret/ptc2 to Gst-Grb2. In fact, all in vitro binding experiments were in agreement with an indirect binding between Ret-iso9 and Grb2. None of the phosphopeptides modeled on Ret-iso9 inhibited the Grb2-Ret/ptc2-iso9 binding and experiments performed with boiling SDS indicated a conformation-dependent interaction.
In cells expressing both isoforms, the long isoform itself could mediate Grb2-Ret-iso9 interaction. In fact, we had previously demonstrated that heterodimerization between the two isoforms can occur (Bongarzone et al., 1993) and, as a consequence, here we have observed that pY620 inhibits the binding of Grb2 with both isoforms.
However, since the indirect interaction between Grb2 and Ret-iso9 is present also when Ret-iso51 is not coexpressed, we have looked for additional proteins that could account for this. The tyrosine phosphatase Syp (Feng et al., 1993) was excluded, since its SH2 domains do not bind either Ret isoforms. Shc, instead, which is known to bind both Ret isoforms (Arighi et al., 1997; Lorenzo et al., 1997) and to coimmunoprecipitate with Grb2 in cells expressing Ret , could work as adaptor protein for this interaction.
Accordingly, when we have used Ret/ptc2-iso9Y586F (Arighi et al., 1997) , a mutant completely unable to bind Shc, the binding to full or SH2 domain of Grb2 was strongly reduced compared with wt, thus indicating that this tyrosine residue (Y1062 on proto Ret) was responsible for the indirect binding to Grb2. Shc could be, therefore, suggested to be the predicted`adaptor molecule'. If Shc is the unique adaptor molecule, we would predict similar Shc-mediated coimmunoprecipitation of Grb2 with Ret/ptc2-iso9wt and Ret/ptc2-iso51Y620F. Instead, the coimmunoprecipitation of Grb2 with Ret/ptc2-iso9wt and Ret/ptc2-iso51Y620F, both displaying Shc binding site, is not similar since Ret/ptc2-iso51Y620F loses about 90% of the wt binding capability. As a consequence, since, according to Lorenzo et al. (1997) Ret-iso9 binds less PTB-and more SH2-Shc domain than Ret-iso51, we should hypothesize that only Shc bound to Ret by its SH2 domain is able to bridge Ret to Grb2. Alternatively, another (others)`adaptor molecule(s)' would exist with high anity only for the sequence downstream to Y586 of iso9 (YGRISH) and not for that of iso 51 (YGMSDP). Dierent tyrosine phosphorylated proteins bound to either Ret/ptc2 isoforms were detected (data not shown) and are currently under investigation.
In conclusion, we have demonstrated that both the Ret isoforms are comparably able to recruit Grb2 in living cells and that, unexpectedly, SH2 domain of Grb2 is not responsible for 100% of the binding to Ret/ptc2, but that either SH3 domain(s) or Grb2 conformation are necessary. In addition, we have demonstrated a dierent recruitment of the adaptor molecule Grb2 by the two Ret isoforms. A direct docking site for Grb2 has been identi®ed in tyrosine 620 of Ret/ptc2, corresponding to tyrosine 1096 of the proto Ret long isoform. The binding to Ret/ptc2-iso9 is, conversely, an indirect one, mediated by Shc and, most likely, by still unidenti®ed protein(s) which preferentially binds the short isoform. Moreover, we have demonstrated that Tyr 620 is essential for the full transforming activity of Ret/ptc2-iso51 and we suggest that in the short isoform the function of this tyrosine residue is replaced by a sequence that is unidenti®ed but that, most likely, is included in the C-terminal short isoform speci®c amino acid sequence.
Materials and methods

Cell culture and transfections
NIH3T3 and COS7 cells were grown in DMEM containing 10% calf serum or 10% fetal calf serum respectively. NIH3T3 (2610 5 ) cells were transfected by calciumphosphate coprecipitation using 500 ng of plasmid DNA and 40 mg of mouse carrier DNA. Transformation foci were selected in DMEM + 5% calf serum ®xed and counted or isolated for the further studies 3 weeks after transfections.
For transient transfection COS7 (1610 6 ) cells were treated with DEAE-dextran method (Arighi et al., 1997) . Before protein extraction, NIH3T3 cells and NIH3T3-derived cell lines were serum starved for 48 h in DMEM plus 0.1% BSA, plus 10 mM HEPES buer.
Site directed mutagenesis and cloning of RET/PTC2 mutants
The cloning of the RET/PTC2-ISO51 and-ISO9 cDNA has been previously reported (Arighi et al., 1997; Bongarzone et al., 1993) . Site directed mutagenesis was performed on pRC-CMV carrying RET/PTC2 wt iso51 cDNA, using an in vitro Oligonucleotide Mutagenesis System (Promega). Oligonucleotide carrying Y620F was: 5'-ATG ATA GTG TAT TTG CTA ACT GGA TGC-3'. Mutant clones were identi®ed by Allele Speci®c Oligonucleotide (ASO) technique using reverse complement oligonucleotide carrying wt (5'-ATA GTG TAT ATG C-TA ACT-3') or Y620F (5'-ATA GTG TAT TTG C-TA ACT-3') sequence.
Full length RET/PTC2-ISO51Y620F cDNA clones were entirely sequenced. The cloning of the RET/PTC2-ISO9Y586F is described in Arighi et al., (1997) .
In vitro binding experiments using Gst-fused protein and phosphopeptides competition Bacterial cultures expressing pGEX vector alone or recombinant pGEX containing the full length GRB2 adaptor protein or Grb2 ± SH2 domain or Grb2 ± SH3 Cterminal domain or Grb2 ± SH3 N-terminal domain, or Syp-SH2 domain, were grown in LB medium containing 100 mg ml 71 ampicillina, induced with 1 mM isopropil bDthiogalactopyrenoside for 3 ± 6 h. The Gst-fused proteins were puri®ed as described in Arighi et al. (1997) . The clari®ed cellular lysates, obtained as described in Borrello et al. (1994) were incubated with 5 ± 40 mg immobilized Gst or Gst-fused proteins for 60 min at 48C. When indicated, 1% SDS was added, protein samples were boiled 5 min and diluted to 0.1% SDS concentration before the incubation with the Gst proteins. Protein complexes were resolved by SDS ± PAGE and transferred to nitrocellulose. Blots were blotted and probed as described in Borrello et al. (1996) .
The peptide competition was performed by using decaphosphopeptides and by preincubating the immobilized Gst-fused protein with the indicated concentration of peptides before adding the cell lysates. In Figure 2 the number of each peptide corresponding to tyrosines of C-terminal of Ret are indicated with the number of Ret/ptc2 tyrosines. The phosphopeptides were synthesized as described in Borrello et al. (1996) . The sequence of each phosphopeptide is shown in Arighi et al. (1997) .
In vitro immunocomplex kinase assay
The anti-Ret immunoprecipitates, adsorbed on protein ASepharose beads, were washed twice with lysis buer, once with incubation buer (50 mM HEPES pH 7.2, 20 mM MgCl 2 , 5 mM MnCl 2 ) and incubated for 15 min at 48C in 20 ml of the same buer containing 0.5 mM DTT, 4 mCi of [g 32 P]ATP (5000 Ci mmol 71 , Amersham) diluted with unlabeled ATP to the ®nal concentration of 26 pmol ATP per sample and 50 mM of myelinic basic protein. The reaction was stopped by addition of concentrated Laemmli buer. Proteins were eluted and subjected to 15% SDS ± PAGE.
32 P-labeled bands were revealed by autoradiography of the dried gel and analysed by PhosphorImager.
Immunoprecipitation and Western blotting
Protein samples were prepared as reported in Borrello et al. (1994) and immunoprecipitated with anity puri®ed antiRet policlonal antiserum (Borrello et. al., 1996) , or with anti-GRB2 (UBI). Where indicated, NIH3T3 cells were stimulated for 15 min at 378C with PDGF BB 50 mg/ml (GIBCO) and the cell extract was immunoprecipitated with anti-PDGF receptor antiserum (UBI). The immunoprecipitates were resolved by SDS ± PAGE, transferred onto nitrocellulose ®lters, and immunoblotted with the anti-Ret antibody described in Borrello et al. (1996) , anti-PTyr (UBI), anti-GRB2 (UBI 05-372) or anti-SHC (UBI). Immunoreactive bands were followed by autoradiography, or using a horseradish peroxidase conjugate anti-rabbit or anti-mouse antiserum and ECL detection system (Amersham) or, visualized using 125 I-labeled protA (Amersham) where indicated or using Western-Star Chemioluminescent Detection System (Tropix, Inc.) only for Figure 5a . When 125 I Protein A was used, the ®lters were exposed to storage phosphor screen ®lms (Molecular Dynamics) and analysed with Phosphor Imager apparatus (Molecular Dynamics) in order to quantify the speci®c band reacting with anti-Ret antiserum.
